Celgene Corp

Article Abstract:

The Food and Drug Administration granted fast track status to Celgene Corp.'s anticancer compound while GlaxoSmithKline granted the company promotion rights to another anticancer agent. Research and development expenses will increase but a small profit is expected in 2003 and 2004.

Sweden, Pharmaceutical industry, Licensing agreements, Licensing, certification and accreditation, United States. Food and Drug Administration, GlaxoSmithKline AB, Celgene Corp., CELG

---

Biotechnology Industry

Article Abstract:

Stocks in the biotechnology industries lost some ground in the market and the effects of President George Bush's policies and Medicare reform legislation's e ffects on the industry are discussed .

Legal issues & crime, Government regulation (cont), Government domestic functions, Legal/Government Regulation, Laws, regulations and rules, Biotechnology industry, Biotechnology industries, Government regulation, Social policy, Bush, George W., Industry forecasts, Health policy

---

Techne Corp

Article Abstract:

Techne Corp.'s market for its products has weakened and its share price dropped by Wall Street, but equity still offers 3 - 5 year capital gains potential.

Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Drugs, Metabolic Agents NEC, Metabolic Agents, Techne Corp., TECH

Similar abstracts:

• Abstracts: Gentex Corp. Gentex Corporation. Centex Corp
• Abstracts: CIGNA Corp. Torchmark Corp
• Abstracts: Cerner Corp
• Abstracts: IDX Systems Corp. Informatica Corp
• Abstracts: Biovail Corp. AMGEN

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.